Using genomics and early treatment response to guide risk-stratification and low-intensity therapy use for ETV6::RUNX1 and high-hyperdiploid B-cell acute lymphoblastic leukemia benefits patients.
Using genomics and early treatment response to guide risk-stratification and low-intensity therapy use for ETV6::RUNX1 and high-hyperdiploid B-cell acute lymphoblastic leukemia benefits patients.